Navigation Links
NeurogesX Announces Resignation of Bruce A. Peacock from Board of Directors
Date:7/17/2009

SAN MATEO, Calif., July 17 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX) announced today that Bruce A. Peacock has resigned from his roles as Audit Committee chairman and director to focus on his responsibilities as CEO of privately-held Alba Therapeutics.

Mr. Peacock commented, "While there is no opportune time to resign, I feel confident that NeurogesX is well positioned following the recent E.U. approval of Qutenza(TM) and the partnership with Astellas Pharma Europe Ltd. to commercialize Qutenza in Europe, and for the ongoing NDA review in the United States. In the wake of these accomplishments I am comfortable leaving NeurogesX while I focus more of my energies on Alba Therapeutics."

Tony DiTonno, NeurogesX CEO commented, "We would like to thank Bruce for all his contributions to NeurogesX during the initial regulatory approval and E.U. partnership discussions surrounding Qutenza. We are disappointed in his resignation but certainly understand the rationale and wish him well in his future endeavors."

Following Mr. Peacock's departure NeurogesX has received a Nasdaq Staff Deficiency Letter dated July 14, 2009 indicating that the company fails to comply with Nasdaq's audit committee composition requirements for continued listing as set forth in Listing Rule 5605(c)(2)(A), which requires that the company's Audit Committee be comprised of at least three members, each of whom are independent.

Consistent with Listing Rule 5605(c)(4)(B) the company has until the earlier of its next annual shareholders' meeting or June 29, 2010 to name a third director as a member of the Audit Committee so that the company regains compliance with the requirements of Listing Rule 5605(c)(2)(A).

An active search for Mr. Peacock's replacement is currently underway and NeurogesX expects to fill the vacancy created by his resignation within the timeframe required by the Nasdaq Listing Rules.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and was given a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to timing for locating and appointing a qualified candidate to fill the vacancy on the Board of Directors and Audit Committee; the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; timing for commercialization of Qutenza; and NeurogesX' plans and expected timing, with regard to seeking partnerships for its product candidates and entry into development programs. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to; positive results in clinical trials may not be sufficient to obtain FDA approval; the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.                     The Ruth Group
    Stephen Ghiglieri                   Sara Pellegrino (investors)
    Chief Financial Officer             (646) 536-7002
    (650) 358-3310                      spellegrino@theruthgroup.com

                                        Jason Rando / Janine McCargo (media)
                                        (646) 536-7025/7033
                                        jrando@theruthgroup.com
                                        jmccargo@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NeurogesX and Astellas Enter Commercialization Agreement for Qutenza(TM)
2. NeurogesX Reports Fourth Quarter and Year-End 2008 Results
3. NeurogesX to Present at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference
4. NeurogesX Reports Fourth Quarter and Year-End 2007 Financial Results
5. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
6. NeurogesX to Present at RBC Capital Markets 2007 Healthcare Conference
7. NeurogesX to Report Third Quarter 2007 Financial Results on November 14, 2007
8. SXC Health Solutions announces contract with largest workers compensation organization in the U.S.
9. Masimo Announces Settlement of Lawsuit
10. NHP Announces Second Quarter Earnings Release Date and Webcast/Conference Call
11. JAG Media Holdings, Inc. Announces a Further Update of the Status of Its Acquisition of CardioGenics Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... 2017 , ... Seamild, the largest manufacturer of oats in China, is now ... founder. As Oat is recognized globally as one of the healthiest cereals, XieQingkui, the ... it is a move to sow the seed of good karma. Buddhism spirit featuring ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics (SRO) ... located at 167 Lynch Creek Way. The Petaluma office features three comfortable patient ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. ...
(Date:1/20/2017)... ... , ... A new partnership between Goodwill® and Roadie, Inc. aims to make ... clothes to couches to dressers and bicycles. Roadie — the national on-the-way delivery network ... donation center through February 28th. , “January is an exciting time when resolutions ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Bionic Sports ... all walks of life, announced it had a successful January ECRM Trade Show in ... in the United States, which allows it to provide its products to all clients ...
(Date:1/20/2017)... ... January 20, 2017 , ... Michael and Betsy Brauser celebrated 5 years of ... the clinical trial has been life-saving as she has been on the trial ... Brauser was diagnosed with ovarian cancer in 2009. She underwent standard chemotherapy but a ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... Research and Markets has announced the addition of the "Advanced ... End User - Forecast to 2025" report to their offering. ... The Global Advanced ... around 7.8% over the next decade to reach approximately $330.70 billion ... markets for Advanced Drug Delivery across all the given segments on ...
(Date:1/20/2017)... 2017 Research and Markets has announced ... Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company ... ... Hearing Aids Market Sales Volume, Company Analysis and Forecast to ... aid industry. The growing prevalence of hearing impairment ...
(Date:1/20/2017)... , Jan 20, 2017 Research and ... Testing Market Trends, Opportunities, and Future" report to their offering. ... This research ... emerging trends, and technologies, and provides a snapshot of the key ... 2015 and forecasts are provided from 2016 to 2020. The market ...
Breaking Medicine Technology: